Edition:
United Kingdom

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

39.52USD
15 Feb 2019
Change (% chg)

$0.45 (+1.15%)
Prev Close
$39.07
Open
$39.22
Day's High
$39.87
Day's Low
$39.22
Volume
22,150
Avg. Vol
37,911
52-wk High
$61.29
52-wk Low
$28.54

Latest Key Developments (Source: Significant Developments)

Anika Reports Third Quarter 2018 Financial Results
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Anika Therapeutics Inc ::ANIKA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.53.Q3 REVENUE $26.8 MILLION VERSUS I/B/E/S VIEW $27 MILLION.Q3 EARNINGS PER SHARE VIEW $0.31 -- THOMSON REUTERS I/B/E/S.ANTICIPATES 2018 FULL YEAR PRODUCT REVENUE TO BE APPROXIMATELY 3% BELOW PRIOR YEAR.ANIKA THERAPEUTICS - CONTINUES TO EXPECT IT WILL RESUME SHIPMENT OF PRODUCTS THAT WERE SUBJECT OF PREVIOUSLY-DISCLOSED VOLUNTARY RECALL BY END OF YEAR.ANIKA THERAPEUTICS - TOTAL OPERATING EXPENSES ARE NOW EXPECTED TO BE REDUCED TO HIGH $80 MILLION RANGE FOR FULL YEAR OF 2018.  Full Article

Anika Announces FDA 510(K) Clearance For Its Injectable HA-Based Bone Repair Treatment
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Anika Therapeutics Inc ::ANIKA ANNOUNCES FDA 510(K) CLEARANCE FOR ITS INJECTABLE HA-BASED BONE REPAIR TREATMENT.ANIKA THERAPEUTICS INC - HA-BASED BONE VOID FILLER RECEIVED 510(K) CLEARANCE FROM U.S. FDA.  Full Article

Anika reports Q3 earnings per share $0.46
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Anika Therapeutics Inc ::Anika reports third quarter 2017 financial results.Q3 earnings per share $0.46.Q3 revenue rose 5 percent to $27.2 million.  Full Article

Anika completes enrollment in second pivotal phase III trial of cingal
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Anika Therapeutics Inc ::Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis.Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis.Anika Therapeutics - ‍Anika expects to complete cingal second pivotal phase III trial in first half of 2018 and anticipates FDA approval following year​.  Full Article

Anika Therapeutics announces regulatory approval for Monovisc® in Australia
Monday, 16 Oct 2017 

Oct 17 (Reuters) - Anika Therapeutics Inc :Anika announces regulatory approval for Monovisc® in Australia for the treatment of pain associated with osteoarthritis of all synovial joints.Anika Therapeutics Inc - ‍Anika intends to further expand Monovisc into additional international markets in 2018​.  Full Article